Inactive Instrument

Press Releases Xintela AB (publ) Nasdaq Stockholm

Equities

Xintela AB publishes Annual Report 2023	Apr. 17	AQ
Xintela: Awaiting results in trials and discussions	Feb. 29	AQ
Xintela AB Year-end Report 2023	Feb. 28	AQ
Xintela appoints Lucienne Vonk as Chief Scientific Officer	Feb. 19	AQ
Targinta's CEO to BioStock: "Strong interest in ADCs in 2023"	Jan. 22	AQ
Xintela newsletter, No. 1 2024	Jan. 19	AQ
First patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers	Dec. 21	AQ
Xintela publishes efficacy results with EQSTEM from preclinical equine OA study	Dec. 20	AQ
Västra Hamnen Corporate Finance initiates coverage of Xintela	Dec. 04	AQ
Xintela’s integrin marker carries hidden value	Dec. 01	AQ
Xintela changes Certified Adviser to Carnegie Investment Bank AB (publ)	Nov. 30	AQ
Xintela AB Interim Report January - September 2023	Nov. 24	AQ
Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study	23-10-13	AQ
Xintela AB Interim Report January - June 2023	23-08-30	AQ
Xintela gets product patent in USA for chondrocyte-based products	23-08-15	AQ
Xintela completes XSTEM dosing at third and final dose level in knee osteoarthritis clinical study	23-06-22	AQ
Xintela publishes positive preclinical results from XSTEM treatment of ARDS	23-06-09	AQ
Xintela's clinical study with XSTEM for knee osteoarthritis makes good progress	23-06-01	AQ
BioStock: Xintela highlights the unique properties of XSTEM	23-05-30	AQ
Xintela AB Interim Report January - March 2023	23-05-25	AQ

No results for this search